Trials / Recruiting
RecruitingNCT04036188
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Wright State University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triamcinolone | Triamcinolone 0.1% daily |
| DIETARY_SUPPLEMENT | Vitamin D3 | 40,000 IU Vitamin D3 daily |
| DRUG | Placebo | Placebo daily |
Timeline
- Start date
- 2019-10-16
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2019-07-29
- Last updated
- 2026-02-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04036188. Inclusion in this directory is not an endorsement.